The Paradigm Biopharmaceuticals share price is up 196% in 2019

The Paradigm Biopharmaceuticals Ltd (ASX:PAR) share price is pushing higher again on Thursday. Is this a small cap healthcare share to buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price was on form again on Thursday.

The biopharmaceutical company's shares pushed 4% higher to $2.93 on the day of its annual general meeting.

This latest gain means the Paradigm share price is now up 196% from 99 cents at the start of the year.

Why did the Paradigm share price push higher today?

This morning Paradigm released its annual general meeting presentation which reminded investors of the massive market opportunity its ZILOSUL drug has.

ZILOSUL is the brand name of its repurposing of Pentosan Polysulfate Sodium (PPS). This is an FDA-approved drug that has been used safely for treating inflammation for over sixty years.

Paradigm is focusing on repurposing PPS to treat osteoarthritis (OA). This is a market with over 31 million sufferers in the United States alone.

Things look very promising for ZILOSUL. Its Phase 2b trial in OA successfully met primary, secondary, and exploratory endpoints.

The company is now planning to file an Investigational New Drug Application (IND) with the FDA for a phase 3 clinical trial in early 2020. Which means there is the potential for a trial readout and regulatory submission in the United States as early as 2021.

Will it be worth the wait?

As you can see on the chart below, the company estimates that ZILOSUL has the potential to generate significant revenues.

Paradigm share price

Should you invest?

At the last count, Paradigm had 193,156,511 shares on issue. This means that it has a market capitalisation of approximately $570 million today.

Clearly if it can win even a 10% share of the U.S. market, its shares would be worth many multiples more than they are today.

This could make it worth considering if you're a patient and long-term focused investor. Especially given its cash balance of ~$75 million. These funds should comfortably see Paradigm through to a commercial launch, if it gets that far.

However, I would suggest you limit an investment to just a small part of your portfolio. After all, there's still a lot of work to do before that is even a possibility.

In addition to Paradigm, I think Clinuvel Pharmaceuticals Limited (ASX: CUV) and Medical Developments International Ltd (ASX: MVP) are worth watching closely as well.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why IGO, Johns Lyng, Lynas, and Web Travel shares are pushing higher today

These shares are ending the week on a high. But why?

Read more »

Happy teen friends jumping in front of a wall.
Share Gainers

Guess which 4 ASX 200 shares are rocking new 52-week highs today!

Investors just sent these four ASX 200 shares to one-year-plus highs.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Evolution Mining, Orthocell, Platinum, and Turaco shares are charging higher

These shares are having a better day that most on Thursday.

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing hump day session for the ASX today.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX managed to bank a small rise this Tuesday.

Read more »

Sport trainer talking to little girl who is climbing wooden ladder in gym.
Share Gainers

Why Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today

These shares are gaining on Tuesday, but why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Financial Shares

5 best ASX 200 financial shares of FY25 (CBA didn't make the cut!)

These stocks were well and truly 'in the black' for share price growth last financial year.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Amaero, Black Cat, Domino's, and Ramelius shares are racing higher today

These shares are having a good session on Tuesday. But why?

Read more »